GOG, Germany.
Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d.
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today?
在 2010 年 6 月于加拿大温哥华举行的妇科癌症协作组（GCIG）第 4 次卵巢癌共识会议上，来自 23 个妇科癌症研究协作组的代表齐聚一堂，就大型随机试验开展过程中的关键问题达成国际共识。该过程重点关注了 13 个预先设定的问题。第 A 组，3 个讨论组之一，负责处理前 5 个问题，研究新诊断卵巢癌患者的一线治疗方法。A1：不同试验（维持治疗、包含分子药物的一线化疗试验）的合适终点是什么？A2：是否存在任何基于肿瘤生物学特征的亚组，需要特定的治疗方案/试验？A3：2004 年 GCIG 推荐的标准对照臂仍然有效吗？A4：改变化疗剂量、方案和给药方式的作用是什么？A5：手术在当今扮演什么角色？
